Skal nok se @laplagam at kursen og epileptikere har en spennende fremtid innen dette studiet med spanjolene👌
1 Like
2 Likes
2 Likes
Forsiktig med å høre på den gjengen der. De har et salg i en av deres trader der kursen aldri har vært innom…
3 Likes
Ja jeg ville selv aldri handlet på den meldingen der 
Burde lagt ved en disclaimer så takk som påpekte det 
Exercise period for warrants of series TO3 in CombiGene AB (publ) begins today
Today, the exercise period for subscription of shares in CombiGene AB (publ) (“CombiGene”) begins on the basis of warrants of series TO3. One warrant of series TO3 entitles to subscription for one new share in CombiGene from and including 17 August 2020 up to and including 31 August 2020 at a subscription price of SEK 0.6 corresponding to the volume-weighted average price of the shares in CombiGene during the period from and including 3 August 2020 up to and including 14 August 2020 with a discount of 30 percent, because the subscription price per share could not be higher than SEK 0.6.
On February 18, 2020, CombiGene issued 26,284,180 warrants of series TO3 and on April 24, CombiGene issued an additional 4,000,000 warrants of the same series, in total CombiGene has issued 30,284,180 warrants of series TO3. In the case of full subscription at the subscription price of SEK 0.6, CombiGene will be granted SEK 18,170,508 before issue costs, with the total number of shares increasing by 30,284,180 shares to 155,906,187 shares and the share capital increasing by SEK 3,028,418 to SEK 15,590,618.7, corresponding to a dilution effect of approximately 19.42 percent of CombiGene’s share capital and votes. Dilution effect refers to the number of newly issued shares and additional votes as a result of full exercise of the warrants of series TO3 in relation to the total number of shares and votes in CombiGene after the new shares have been registered.
Please note that if the warrants of series TO3 are not exercised for subscription of shares by August 31, 2020 at the latest or disposed of by August 27, 2020 at the latest, they will expire and lose their value and will be cleared from the VP account or depositary.
The application form, the Board’s report and auditor’s statement as well as the full terms and conditions for the warrants of series TO3, a copy of CombiGene’s Articles of Association, a copy of the annual report containing the most recently established balance sheet and income statements, including the audit report for the financial year, are available at the Company and on the Company’s website, www.combigene.com.
The results of the exercise period will be announced in September 2020.
2 Likes
De jobber på, veldig bra!
2 Likes
Noen grunner til å investere i genterapi.
https://www.carnegie.se/private-banking/Aktuellt/framtidens-lakemedel/
2 Likes
Da er H1 rapporten ute:
2 Likes
CombiGene applies for patent protection for vectors developed in the lipodystrophy project CGT2
CombiGene has filed a priority patent application with the UK Patent Office for patent protection for the vectors developed within the Company’s lipodystrophy project CGT2. The filing of this patent application paves the way for global patent protection for CGT2, which is of great importance for protecting key functions of CGT2 during the further development and commercialization.
The CGT2 project aims to develop a gene therapeutic treatment for partial lipodystrophy. The project was inlicensed from Lipigon Pharmaceuticals AB 2019 and is in early preclinical development with a focus on design and testing of gene therapy vectors.
”Since we licensed the project from Lipigon 2019, the pace has accelerated, and we are now beginning to see the first fruits of this work. The filing of the patent application is an early milestone in this very exciting project,” says Annika Ericsson, Senior Project Manager at CombiGene.
2 Likes
CombiGene AB (publ) announces the outcome of the exercise of warrants of series TO 3
On August 31, 2020 the period for exercising warrants of series TO 3 for subscription of shares in CombiGene AB (publ) (“CombiGene” or “The Company”) ended. In total, 29 450 679 warrants had been exercised for subscription of shares and each warrant entitled to subscribe for one (1) new share in CombiGene at a subscription price of SEK 0.6 per share. The utilization rate thus amounted to approximately 97,25 per cent and through the warrants CombiGene was granted SEK 17 670 407,40 before issue costs.
The subscription entails that the number of shares in CombiGene increases with 29,450,679 shares, from 147,210,132 shares to 176,660,811 shares and that the share capital increases by SEK 2,945,067.9 from SEK 14,721,013.2 to SEK 17,660,081.10.
The shares added as a result of the exercise of warrants of series TO 3 entails a dilution effect of approximately 16,67 per cent. Dilution effect refers to the number of newly issued shares as a result of exercised warrants of series TO 3 in relation to the total number of shares in CombiGene after the new shares have been registered.
2 Likes
Har vært litt diverse bevegelser i innsidehandel i det siste men ikke noe av voldsom betydning såvidt jeg kan se:
Rett meg gjerne om jeg tar feil men:
Jan Nilsson solgte 127k TO3
Peter Nilsson subscribet for 150k TO3
Per Lundin kjøpte 30612 aksjer
Edit: Mulig jeg tar feil og at Jan også har subscribet for alle opsjonene selv om datoen er litt rar.
Edit 2: Jeg tror Jan solgte 127k TO3 og dermed fikk inn ~30k kroner. Deretter kjøpte han 127k Combiaksjer i markedet. Man kan jo spekulere i om han gjorde dette for å hjelpe med å holde kursen oppe for å sikre fulltegning. I såfall en fin liten bonus.
2 Likes
Veldig bra, dette lover bra.
2 Likes
Genom avtalet med Viralgen tar CombiGene ett stort steg mot att ha en komplett produktionsmetod på plats. De få bitar som saknas för att starta en storskalig produktion räknar vi med att få plats inom en nära framtid. Vi befinner oss därmed i en position där vi snart har allt på plats för att börja producera material för de avslutande prekliniska studierna, bland annat toxikologi- och biodistributionsstudierna«, säger Jan Nilsson, vd CombiGene i en kommentar till BioStock
Nærmer seg veldig at de kan begynne med sikkerhetsstudiet nå 
1 Like
Combigene live fra Aktiedagen i morgen klokken 10:20.
2 Likes
Artikkel med Combis nye styreleder:
1 Like
Combi ansetter.
2 Likes
CombiGene carries out a directed new issue of shares to Lipigon Pharmaceuticals
The board of directors of CombiGene AB (publ) (“CombiGene”) has, on the basis of an authorization from the Annual General Meeting, resolved on a directed share issue of 1,561,365 shares to Lipigon Pharmaceuticals AB (“Lipigon”) due to the license agreement previously concluded between CombiGene and Lipigon.
The share issue is carried out in order to pay the second interim payment to Lipigon under the license agreement. The second interim payment amounts to SEK 1,499,999.63 and is paid by a new issue of 1,561,365 shares. The number of shares has been determined on the basis of a subscription price corresponding to the volume weighted average price of CombiGene’s share during a period of fifteen (15) trading days ending the day before the board of director’s resolution on the issue of shares.
The interim payment follows CombiGene’s patent protection application for vectors developed within the lipodystrophy project CGT2, made on 24 August 2020. For further information on the patent application see press release “CombiGene applies for patent protection for vectors in the lipodystrophy project CGT2” from 25 August 2020. The share issue represents a dilution of approximately 0.88 percent of the share capital of CombiGene after the share issue. The new shares will be transferred to Lipigon as soon as the issue has been registered with the Swedish Companies Registration Office.
1 Like
Tror dette er veldig positivt å få disse inn på eier siden. Selskapene har naturligvis felles interesser, samtidig som Lipigon allerede har flere samarbeid med AstraZeneca, noe jeg tror kan være nyttig etterhvert som CombiGene etterhvert må se etter partnere. Skjer mye spennende i selskapet for tiden.
1 Like